-
Je něco špatně v tomto záznamu ?
ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells
J. Holcakova, M. Nekulova, P. Orzol, R. Nenutil, J. Podhorec, M. Svoboda, P. Dvorakova, M. Pjechova, L. Hernychova, B. Vojtesek, PJ. Coates,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2005-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- buněčná adheze genetika MeSH
- epidermální růstový faktor genetika metabolismus MeSH
- erbB receptory genetika MeSH
- invazivní růst nádoru genetika MeSH
- lidé MeSH
- membránové proteiny genetika MeSH
- metastázy nádorů MeSH
- nádorové buněčné linie MeSH
- proliferace buněk genetika MeSH
- proteomika MeSH
- regulace genové exprese u nádorů MeSH
- signální transdukce MeSH
- triple-negativní karcinom prsu farmakoterapie genetika patologie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: The basal-A subtype of triple-negative breast cancer is characterized by high levels of ΔNp63. Various functions have been proposed for p63 in breast cancer initiation and growth, and p63 mediates chemotherapeutic response in a subset of triple-negative breast cancers. We investigated the signaling pathways that are controlled by ΔNp63 in basal-A triple-negative breast cancer. METHODS: Human basal-A triple-negative breast cancer cell lines with ΔNp63α induction or inhibition were studied, along with primary human triple-negative breast cancer tissues. Proteomic, phospho-kinase array, mRNA measurements, and immunohistochemistry were employed. RESULTS: Global phosphoproteomics identified increased EGFR phosphorylation in MDA-MB-468 cells expressing ΔNp63α. ΔNp63α expression increased EGFR mRNA, total EGFR protein, and phospho-EGFR(Y1086), whereas silencing endogenous ΔNp63 in HCC1806 cells reduced both total and phospho-EGFR levels and inhibited the ability of EGF to activate EGFR. EGFR pathway gene expression analysis indicated that ΔNp63 alters EGFR-regulated genes involved in cell adhesion, migration, and angiogenesis. Addition of EGF or neutralizing EGFR antibodies demonstrated that EGFR activation is responsible for ΔNp63-mediated loss of cellular adhesion. Finally, immunohistochemical staining showed that p63-positive triple-negative breast cancers were more likely to express high levels of EGFR than p63-negative cancers, corroborated by in silico analysis of gene expression profiling data. CONCLUSIONS: These data identify EGFR as a major target for ΔNp63 regulation that influences cancer cell adhesion in basal-like triple-negative breast cancer.
Clinic of Comprehensive Cancer Care Zluty kopec 7 65633 Brno Czech Republic
RECAMO Masaryk Memorial Cancer Centre Zluty kopec 7 65633 Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010719
- 003
- CZ-PrNML
- 005
- 20180419102152.0
- 007
- ta
- 008
- 180404s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10549-017-4216-6 $2 doi
- 035 __
- $a (PubMed)28349272
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Holcakova, Jitka $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
- 245 10
- $a ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells / $c J. Holcakova, M. Nekulova, P. Orzol, R. Nenutil, J. Podhorec, M. Svoboda, P. Dvorakova, M. Pjechova, L. Hernychova, B. Vojtesek, PJ. Coates,
- 520 9_
- $a PURPOSE: The basal-A subtype of triple-negative breast cancer is characterized by high levels of ΔNp63. Various functions have been proposed for p63 in breast cancer initiation and growth, and p63 mediates chemotherapeutic response in a subset of triple-negative breast cancers. We investigated the signaling pathways that are controlled by ΔNp63 in basal-A triple-negative breast cancer. METHODS: Human basal-A triple-negative breast cancer cell lines with ΔNp63α induction or inhibition were studied, along with primary human triple-negative breast cancer tissues. Proteomic, phospho-kinase array, mRNA measurements, and immunohistochemistry were employed. RESULTS: Global phosphoproteomics identified increased EGFR phosphorylation in MDA-MB-468 cells expressing ΔNp63α. ΔNp63α expression increased EGFR mRNA, total EGFR protein, and phospho-EGFR(Y1086), whereas silencing endogenous ΔNp63 in HCC1806 cells reduced both total and phospho-EGFR levels and inhibited the ability of EGF to activate EGFR. EGFR pathway gene expression analysis indicated that ΔNp63 alters EGFR-regulated genes involved in cell adhesion, migration, and angiogenesis. Addition of EGF or neutralizing EGFR antibodies demonstrated that EGFR activation is responsible for ΔNp63-mediated loss of cellular adhesion. Finally, immunohistochemical staining showed that p63-positive triple-negative breast cancers were more likely to express high levels of EGFR than p63-negative cancers, corroborated by in silico analysis of gene expression profiling data. CONCLUSIONS: These data identify EGFR as a major target for ΔNp63 regulation that influences cancer cell adhesion in basal-like triple-negative breast cancer.
- 650 _2
- $a buněčná adheze $x genetika $7 D002448
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x genetika $7 D049109
- 650 _2
- $a epidermální růstový faktor $x genetika $x metabolismus $7 D004815
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a membránové proteiny $x genetika $7 D008565
- 650 _2
- $a invazivní růst nádoru $x genetika $7 D009361
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a proteomika $7 D040901
- 650 _2
- $a erbB receptory $x genetika $7 D066246
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a triple-negativní karcinom prsu $x farmakoterapie $x genetika $x patologie $7 D064726
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nekulova, Marta $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Orzol, Paulina $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Nenutil, Rudolf $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Podhorec, Jan $u Clinic of Comprehensive Cancer Care, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Svoboda, Marek $u Clinic of Comprehensive Cancer Care, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Dvorakova, Petra $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Pjechova, Mariana $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Hernychova, Lenka $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic.
- 700 1_
- $a Vojtesek, Borivoj $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic. vojtesek@mou.cz.
- 700 1_
- $a Coates, Philip J $u RECAMO, Masaryk Memorial Cancer Centre, Zluty kopec 7, 65633, Brno, Czech Republic. philip.coates@mou.cz.
- 773 0_
- $w MED00009361 $t Breast cancer research and treatment $x 1573-7217 $g Roč. 163, č. 3 (2017), s. 475-484
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28349272 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180419102253 $b ABA008
- 999 __
- $a ok $b bmc $g 1288204 $s 1007531
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 163 $c 3 $d 475-484 $e 20170327 $i 1573-7217 $m Breast cancer research and treatment $n Breast Cancer Res Treat $x MED00009361
- LZP __
- $a Pubmed-20180404